Exclusive: India May Lean Toward Powerful Trade Body To Shore Up Low-cost Drug Program
This article was originally published in PharmAsia News
If effective, Jan Aushadhi will play a vital role in generic drug distribution and impact industry profitability.
You may also be interested in...
NEW DELHI - India's government is seeking applications from pharmaceutical companies, non-governmental organizations and other groups as partners for a push to open a chain of low-cost generic drug stores
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.